Ignite Creation Date:
2024-05-06 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05829187
Status:
COMPLETED
Last Update Posted:
2023-05-16
First Post:
2023-01-09
Brief Title:
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Sponsor:
Syamsudin AbdillahPhD Pharm D
Organization:
Pancasila University
Study Overview
Official Title:
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria in Sumba Barat Daya District of Indonesia
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MCHUPF
Brief Summary:
Currently the first-line combination of artemisinin piperaquine and prima-quine is quite effective in controlling malaria however the threat of spread of drug-resistant parasites has been reported A study is conducted to assess the efficacy and safety extract of bitter melon Momordica charantiaMC regimens compared to the combination of dihydroartemisinin piperaquine primaquine DHPPQ on the sexual and asexual stage of P Falciparum uncomplicated in Sumba Barat Daya District Indonesia
Detailed Description:
The Study was conducted in Kori Primary Health Cender Sumba Barat Daya District East Nusa Tenggara Province on Sumba Island
The study subject received either 3 day of dihydroartemisinin-piperaquine and primaquine 1 day on first day DHPPQ or extract of bitter melon Momordica charantiaMC Placebo 1 day on first day according to their body weight
Patients with fever or history of fever within the past 24 hours were screened by microscopic examination of giemsa stained tihick blood films to detect Plasmodium falciparum infection
All Patient were allocated by single blind randomization to receive DHP on day 0 to day 2PQ on day 0 only or extract of bitter melon Momordica charantiaMC on day 0 to day 2placebo on day 0 only The procedures of drug administration in the study were as follows
The study subject received either 3 day of dihydroartemisinin-piperaquine and primaquine 1 day on first day DHPPQ or extract of bitter melon Momordica charantiaMC Placebo 1 day on first day according to their body weight
Patients with fever or history of fever within the past 24 hours were screened by microscopic examination of giemsa stained tihick blood films to detect Plasmodium falciparum infection
All Patient were allocated by single blind randomization to receive DHP on day 0 to day 2PQ on day 0 only or extract of bitter melon Momordica charantiaMC on day 0 to day 2placebo on day 0 only The procedures of drug administration in the study were as follows
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None